-
公开(公告)号：US08933236B2
公开(公告)日：2015-01-13
申请号：US13899469
申请日：2013-05-21
Applicant: Genentech, Inc. , Xenon Pharmaceuticals Inc.
Inventor： Sultan Chowdhury , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Daniel Ortwine , Brian Safina , Shaoyi Sun , Daniel P. Sutherlin , Alla Yurevna Zenova
IPC: C07C311/51 , C07D403/12 , C07D213/82 , C07D213/64 , C07D205/04 , C07D311/58 , A61K31/445 , A61K31/44 , A61K31/18 , C07D265/30 , C07D233/84 , C07D257/04 , C07C307/06 , C07D295/26 , C07D207/48 , C07D311/70 , C07D413/12 , C07D451/02 , C07D307/12 , C07D309/08 , C07D311/72 , C07D405/12 , C07D491/107 , C07D211/22 , C07D295/192 , C07D211/96 , C07D307/18
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Abstract translation: 本发明提供具有以下通式的新化合物及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，B，R1，R2，R3，R4，R5和RN具有 本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。
-
公开(公告)号：US20130317001A1
公开(公告)日：2013-11-28
申请号：US13899526
申请日：2013-05-21
Applicant: XENON PHARMACEUTICALS INC. , GENENTECH, INC.
Inventor： Jean-Christophe Andrez , Sultan Chowdhury , Shannon Marie Decker , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Jun Li , Daniel F. Ortwine , Brian Safina , Tao Sheng , Shaoyi Sun , Daniel P. Sutherlin , Michael Scott Wilson , Alla Yurevna Zenova
IPC: C07D403/12 , C07D213/64 , C07D205/04 , C07D311/58 , C07D295/26 , C07D233/84 , C07D257/04 , C07C311/51 , C07C307/06 , C07D213/82 , C07D265/30
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
-
![PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE](/abs-image/US/2013/08/29/US20130225557A1/abs.jpg.150x150.jpg)
3.发明申请PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE 失效吡咯并[3,2-d]吡嗪PI3K DELTA抑制剂化合物及其使用方法公开(公告)号：US20130225557A1
公开(公告)日：2013-08-29
申请号：US13854635
申请日：2013-04-01
Applicant: Genentech, Inc.
Inventor： Georgette Castanedo , Bryan Chan , Matthew C. Lucas , Brian Safina , Daniel P. Sutherlin , Zachary Sweeney
IPC: C07D471/04 , C07D491/107
CPC classification number: C07D471/04 , C07D491/107
Abstract: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Abstract translation: 式I化合物，包括立体异构体，几何异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学障碍和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
公开(公告)号：US10071957B2
公开(公告)日：2018-09-11
申请号：US14413218
申请日：2013-07-05
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor： Christoph Martin Dehnhardt , Sultan Chowdhury , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Brian Safina , Daniel P. Sutherlin
IPC: C07D205/04 , C07D209/08 , C07D213/63 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/20 , C07D217/02 , C07D231/56 , C07D277/24 , C07D277/34 , C07D277/62 , C07D305/08 , C07D401/12 , C07D405/12 , C07D413/12 , C07C307/06
CPC classification number: C07C307/06 , A61K31/44 , A61K31/4439 , A61K31/444 , C07C2601/04 , C07D205/04 , C07D209/08 , C07D213/63 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/20 , C07D217/02 , C07D231/56 , C07D277/24 , C07D277/34 , C07D277/62 , C07D305/08 , C07D401/12 , C07D405/12 , C07D413/12
Abstract: The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
-
公开(公告)号：US08952169B2
公开(公告)日：2015-02-10
申请号：US13899526
申请日：2013-05-21
Applicant: Genentech, Inc. , Xenon Pharmaceuticals Inc.
Inventor： Jean-Christophe Andrez , Sultan Chowdhury , Shannon Marie Decker , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Jun Li , Daniel F. Ortwine , Brian Safina , Tao Sheng , Shaoyi Sun , Daniel P. Sutherlin , Michael Scott Wilson , Alla Yurevna Zenova
IPC: C07C311/51 , C07D403/12 , C07D213/82 , C07D213/64 , C07D205/04 , C07D311/58 , A61K31/445 , A61K31/44 , A61K31/18 , C07D265/30 , C07D233/84 , C07D257/04 , C07C307/06 , C07D295/26 , C07D207/48 , C07D311/70 , C07D413/12 , C07D451/02 , C07D307/12 , C07D309/08 , C07D311/72 , C07D405/12 , C07D491/107 , C07D211/22 , C07D295/192 , C07D211/96 , C07D307/18
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US09309265B2
公开(公告)日：2016-04-12
申请号：US14446154
申请日：2014-07-29
Applicant: Genentech, Inc. , F. HOFFMANN—LA ROCHE AG
Inventor： Steven Do , Richard Goldsmith , Tim Heffron , Aleksandr Kolesnikov , Steven Staben , Alan G. Olivero , Michael Siu , Daniel P. Sutherlin , Bing-Yan Zhu , Paul Goldsmith , Tracy Bayliss , Adrian Folkes , Neil Pegg
IPC: A01N37/00 , C07D333/00 , C07F5/02 , C07D495/04 , C07D495/14 , C07D513/14 , A61K31/381 , A61K31/4155 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/4436 , A61K31/496 , A61K31/53
CPC classification number: C07F5/02 , A61K31/381 , A61K31/4155 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/4436 , A61K31/496 , A61K31/53 , C07D495/04 , C07D495/14 , C07D513/14
Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Abstract translation: 式I和II的苯并吡喃和苯并辛菌素化合物，包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗疾病如癌症 由脂质激酶介导。 公开了使用式I和II的化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
公开(公告)号：US20150224071A1
公开(公告)日：2015-08-13
申请号：US14558440
申请日：2014-12-02
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor： Sultan Chowdhury , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Daniel Ortwine , Brian Safina , Shaoyi Sun , Daniel P. Sutherlin , Alla Yurevna Zenova
IPC: A61K31/18 , A61K31/397 , A61K31/40 , A61K31/5375 , A61K31/41 , A61K31/44 , A61K31/4164
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Abstract translation: 本发明提供具有以下通式的新化合物及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，B，R1，R2，R3，R4，R5和RN具有 本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。
-
8.发明授权公开(公告)号：US08846762B2
公开(公告)日：2014-09-30
申请号：US13738846
申请日：2013-01-10
Applicant: Genentech, Inc. , F. Hoffmann—La Roche AG
Inventor： Steven Do , Richard Goldsmith , Tim Heffron , Aleksandr Kolesnikov , Steven Staben , Alan G. Olivero , Michael Siu , Daniel P. Sutherlin , Bing-Yan Zhu , Paul Goldsmith , Tracy Bayliss , Adrian Folkes , Neil Pegg
IPC: A01N37/00 , C07D333/00 , A61K31/4365 , A61K31/4196 , A61K31/53 , C07D495/04 , A61K31/496 , A61K31/427 , A61K31/429 , A61K31/4155 , C07D495/14 , A61K31/4245 , A61K31/4436 , C07D513/14 , A61K31/381
CPC classification number: C07F5/02 , A61K31/381 , A61K31/4155 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/4436 , A61K31/496 , A61K31/53 , C07D495/04 , C07D495/14 , C07D513/14
Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Abstract translation: 式I和II的苯并吡喃和苯并氧杂环己酮化合物，包括立体异构体，几何异构体，互变异构体溶剂合物，代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗疾病如癌症介导 通过脂质激酶。 公开了使用式I和II的化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
公开(公告)号：US20170002017A1
公开(公告)日：2017-01-05
申请号：US15017282
申请日：2016-02-05
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor： Jean-Christophe Andrez , Sultan Chowdhury , Shannon Marie Decker , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Jun Li , Daniel F. Ortwine , Brian Safina , Tao Sheng , Shaoyi Sun , Daniel P. Sutherlin , Michael Scott Wilson , Alla Yurevna Zenova
IPC: C07D491/107 , C07C311/51 , C07D307/12 , C07D213/82 , C07D205/04 , C07D207/48 , C07D295/26 , C07D257/04 , C07D311/58 , C07D209/52 , C07D307/18 , C07D211/22 , C07D233/84
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，B，R1，R2，R3，R4，R5和RN具有本文所述的含义， 化合物和使用这些化合物和组合物的方法。
-
公开(公告)号：US20160297754A1
公开(公告)日：2016-10-13
申请号：US15133030
申请日：2016-04-19
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor： Sultan Chowdhury , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Daniel Ortwine , Brian Safina , Shaoyi Sun , Daniel P. Sutherlin , Alla Yurevna Zenova
IPC: C07C311/51 , C07D213/82 , C07D213/64 , C07D205/04 , C07D471/08 , C07D405/12 , C07D295/26 , C07D233/84 , C07D257/04 , C07D207/46 , C07C307/06 , C07D311/58
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，B，R1，R2，R3，R4，R5和RN具有本文所述的含义， 化合物和使用这些化合物和组合物的方法。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.031 seconds)
